The objective of this instrument is to provide exposure to companies advancing biotechnology, genomics, and personalised healthcare solutions. The selection includes firms engaged in genetic research, diagnostics, life-science tools, and innovative biopharmaceutical development. The instrument seeks to reflect the long-term potential of healthcare innovation as a driver of improved medical outcomes and industry transformation. Returns may be influenced by regulatory decisions, clinical results, ethical considerations, and market conditions.